7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 1/37
Immunosuppressants
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 2/37
Very, very powerful Immunosuppressants available
Non-Pharmacological:• Irradiation• Plasmapheresis removal of autoantibodies in diseases like MG
Pharmacological:
• deplete T cells or B cells completely with anti-CD3or anti-CD20 antibodies
• chemotherapy• calcineurin inhibitors, steroids
Problem: Immunosuppression (infections)
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 3/37
Side-Effects of Immunosuppressants
1) General Side Effect: Immunosuppression
• Reactivation of latent viral infections
(e.g. herpes, varicella, CMV, PML)
• Bacterial and fungal infections
• Bone marrow suppression• Increased risk of cancer
2) Specific Side Effects:• Nephrotoxicity of the calcineurin inhibitors
• Metabolic changes with steroids
• “cytokine release syndrome” with anti-CD3 Ab
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 4/37
Corticosteroids
broad anti-inflammatory effects
High dose pulses of i.v. methylprednisolone (SOLU-MERDOL, A-METHAPRED) used to reverse acute
transplant rejection and acute exacerbations of autoimmune diseases like MS or SLE
also used to suppress allergic reactions to biologics (e.g.first-dose cytokine storm in transplantation with
muromonad-CD3 or thymoglobulin)
Invaluable for short-term use!!!
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 5/37
Cytotoxic Agents
Are typically covered in Oncology.
For this lecture it is sufficient you to know that all
cytotoxic drugs that are used for cancer therapyalso hit all fast dividing cells in the body:• immune system• gut mucosa
• hair follicles
Cyclophosphamide and methotrexate often
used in RA and MS
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 6/37
Calcineurin Inhibitors:
• Cyclosporine
• Tacrolimus
Bind to immunophilins (cyclophilin or FK506-binding protein [FKBP]) forming a complex thatinhibits calcineurin
Calcineurin does not dephosphorylate NFAT
NFAT does not translocate to the nucleus
Inhibition of T cell proliferation and IL-2production
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 7/37
Cyclosporine (Cyclosporin A)
cyclic 11 amino acid polypeptide (very lipophilic,orally absorbed)
very effective against T cell dependent responses,less effective against B cells
Therapeutic uses:• kidney, liver, heart and other organ transplantation• severe cases of RA• severe disabling psoriasis where other therapies have failed
Pharmacokinetics:• Administered i.v. (SANDIMMUNE Injection) or orally• oral availability 20-50% [Different formulations like SANDIMMUNEgelatine capsules and NEORAL microemulsion are NOT bioequivalent;should not be freely substituted!!!]
• plasma peak between 1.5 to 2 h; t1/2 5-18 hours• extensively metabolized through CYP3A4; excreted through bile Plasma drug levels must be monitored, drug interactions avoided
and doses adjusted for hepatic insufficiency
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 8/37
Drug Interactions with Cyclosporine
any drug that is metabolized through CYP3A4 affects CsA metabolism
CYP3A4 blockers (ketoconazole, fluconazole, verapamil, idinavir, grapefruit juice) increase CsA plasma levels
CYP3A4 inducers (phenobarbital, phenytoin) reduce CsA plasma levels
Cyclosporine Side Effects1. Nephrotoxicity: occurs in nearly all patients cessation
or modification of therapy2. Hypertension: occurs in ~50% of kidney and 100% of
heart transplant patients3. Hyperlipidemia4. Tremor 5. Hirsutism and hypertrichosis
6. Diabetogenic in combination with glucocorticoids
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 9/37
Tacrolimus (FK506)
macrolide antibiotic produced by Streptomyces tsukunaensis available for oral and i.v. administration (PROGRAF)
t1/2 ~12 hours, PK variable. Metabolized through CYP3A4(same interactions like CsA)
Therapeutic Uses:• Similar to CsA but much less commonly used• “Rescue Therapy” in patients who show rejection
despite therapeutic CsA plasma levels
Side Effects:• Same as CsA, nephrotoxicity is limiting
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 10/37
Sirolimus (Rapamycin)
RAPAMUNE
Macrocyclic lactone produced by Streptomyceshygroscopicus (soil of Easter Islands)
Originally developed by Wyeth as an antifungalwhen it was found to be an immunosuppressant
Mechanism of Action:• Inhibits T cell activation downstream of the IL2 receptor by binding tothe immunophilin FKBP-12
sirolismus-FKBP-12 complex inhibits the protein kinase mTOR(mammalian target of rapamycin), which is a key enzyme in cell-
cycle progression cell cycle arrested in G1-S phase transition
PK:• oral availability ~15%, plasma peak after 1-2 hours, t1/2 = 62 h,
metabolized by CYP3A4
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 11/37
Sirolimus continued
Therapeutic Uses (introduced in 1999):
• used in combination with calcineurin inhibitors andglucocorticoids for organ transplantation (Synergy!!)
• in patients experiencing or at high risk for calcineurin-inhibitor associated nephrotoxicity used with glucocorticoids andmycophenolate mofetil to avoid permanent renal damage
• also coated onto stents to prevent restenosis followingangioplasty
Side Effects:
• increase in cholesterol and triglycerides• delayed wound healing ( often started delayed after surgery)
• much less nephrotoxic than calcineurin inhibitors but carrieswarning about associated nephrotoxicity since Oct. 2008
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 12/37
Cyclosporine and Sirolismus (rapamycin) are synergistic
Often combined to reduce CsA toxicity
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 13/37
Azathioprine (IMURAN)N
N NH
N
S N
NO2N
CH3
Mechanism of Action (Antimetabolite):Cleaved by nucleophiles like glutathione to 6-mercaptopurine Inhibits purine synthesis and thus cell proliferation
Therapeutic Uses:• in combination for organ transplantation• severe RA
Side Effects:• bone marrow suppression (leukopenia, sometimes thrombocytopenia)• hepatotoxicity• increased risk of infections and cancer
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 14/37
Mycophenolate Mofetil
(CELLCEPT)
Prodrug (2-morpholinoethyl ester) that is rapidly hydrolyzed to mycophenolicacid (MPA), which is a reversible inhibitor of ionosine monophosphatedehydrogenase (IMPDH), an enzyme involved in guanine nucleotide synthesis
T and B cells highly dependent on guanine nucleotide synthesis ( other
cells can use other pathways) MPA inhibits T cell and B cell proliferation aswell as antibody production
O
OH
O
OOH
MeO
Mycophenolic acid (MPA)
Therapeutic Uses:• Prevention of transplant rejection (typically in combination withglucocorticoids and calcineurin inhibitors)
• approved for renal transplant in 1995, other transplants later; indicationsmight widen in the future
Side Effects:• Leukopenia• Increased incidence of infections (in June 2006 Roche and FDA issued
warning about PML; 17 cases, 7 fatal)
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 15/37
Progressive Multifocal Leukoencephalopathy (PML)
PML is a rare demyelinating disease of the CNS that usually is fatalor leads to severe disability. PML is caused by reactivation of the JCvirus, a polyomavirus that resides latently in 70-90% of adultsworldwide.
PML presents with ataxia, hemiparesis, confusion, apathy, cognitivedeficiencies and radiographic evidence of white matter disease.
PML should be considered in any transplant or autoimmune diseasepatient who is on immunosuppression and who presents withneurological symptoms.
Other than reducing the dose of immunosuppressant there are nointerventions that can stop or treat PML.
[see also Natalizumab for MS treatment]
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 16/37
FTY720
NH2
OH
OH
Fingolimod (FTY720) is sphingosine-1-phosphate receptor 1 agonistthat prevents egress of lymphocytes from lymph nodes
was not superior to calcineurin inhibitors in Phase-3 clinical trial for kidney transplantation as a monotherapy
Very encouraging effects in Phase-2 clinical trial for MS (relapse rate
reduced by 80%); various other trials going on
FTY720 sequesters T cells in
lymph nodes and preventsthem from recirculating
Will probably become a newdrug for combination therapy
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 17/37
Antithymocyte Globin (THYMOGLUBIN)
Purified gamma globulin fraction from the serum of rabbits immunized withhuman thymocytes
contains cytotoxic Abs that bind to CD2, CD3, CD4, CD8, CD11a, CD18,CD25, CD45 and MHC class I and II (and probably a lot more!!)
Abs deplete circulating lymphocytes by direct cytotoxicity (complement andcell mediated) and block cell surface receptors
Therapeutic Uses:• Approved for acute renal transplant rejection• Often used immediately after kidney transplant if graft function is
delayed to avoid early use of nephrotoxic calcineurin inhibitors
Toxicity:• Polyclonal rabbit Ab xenogenic protein elicits acute allergicreactions (fever, chill, hypotension) premedication withglucocorticoids, acetaminophen and antihistamines
• Anti-ATG Abs develop but do not limit repeated use
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 18/37
Anti-CD3 Monoclonal Antibodies
Antibodies directed against the e chain of the T cells receptor CD3 treatment induces rapid internalization of the TCR and is followed
by depletion and extravasation of T cells from the blood andlymphoid organs (redistribution to the lungs)
Muromonab-CD3 (OKT3) original mouse IgG2a introduced in 1986 Fully humanized Ab: hOKTg1; less cytokine release
Therapeutic Uses:• Mouse Ab still used to reverse glucocorticoid resistant rejection episodes(repeated use results in neutralizing Abs)• Humanized Ab for treatment and prevention of acute rejection• Phase-2/3 clinical trials for prevention of T1DM
Side Effects:• “cytokine release syndrome” typically 30 min after infusion (TNFa, IL2, IL6,INFg from activated T cells and macrophages) high fever, chills, tremor (worst on first dose)• Glucocorticoid administration on first dose is now standard
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 19/37
Rituximab (RITUXAN)
monoclonal anti-CD20 Ab approved in 1997 for the treatment of B-
cell non-Hodgkin lymphomas binds to CD20 on the surface of B cells and seems to induceapoptosis of CD20+ cells and/or induce complement and cell mediatedcytotoxicity (ADCC), drastically reduces number of circulating B cells
Therapeutic Uses:• Leukemia, lymphoma [see Hem/Onc]• In combination with methotrexate for severe RA• Clinical trials ongoing for various autoimmune diseases includingidiopathic autoimmune hemolytic anemia, MS, T1DM, Sjogren's
syndrome, SLE
Side Effects:• Infusion reactions similar to anti-CD3 Abs• Immunosupppression [carries Box Warning about PML]
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 20/37
Anti-CD25 (Anti-IL-2 Receptor)
Daclizumab (ZENAPAX): humanized chimeric monoclonal Ab
Basiliximab (SIMULET): murine-human chimeric monoclonal Ab
both Abs seem to inhibit activated T cells without significant depletion
Therapeutic Uses:• Prophylaxis of acute transplant rejection (pre-operatively andafterwards in biweekly intervals)• Combination for maintenance therapy with other immuno-suppressants (azathioprine, glucocorticoids, cyclosporine)
Side Effects:• no cytokine release syndrome• anaphylaxis can occur
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 21/37
Abatacept (ORENCIA)
fusion protein composed of humanimmunoglobulin fused to the extra-cellular domainof CTLA-4
Costimulation of CD28 through B7-1/2(CD80/CD86) is necessary for full activation of naïve T cells; Engagement of the related receptor
CTLA-4 inhibits/reduces T cell activation Abatacept prevents co-stimulation and canpotentially induce tolerance
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 22/37
Abatacept continued
Therapeutic Uses:• Currently approved for RA patients who have failedmethotrexate and anti-TNF reagents• Currently in clinical trials for T1DM prevention, colitis,
psoriasis and transplant rejection
Side Effects:• usual risk of increased infections and malignancies
• should not be used in combination with TNF-antagonist (no additional benefit and greatly increasedrisk of infections)
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 23/37
Anti-TNF Reagents
Infliximab (REMICADE): chimeric anti-TNF-a monoclonal Ab containing
a human constant and a murine variable region; binds with high affinity to
TNF-a and prevents it from binding to its receptor
Etanercept (ENBREL): Fusion protein of Fc portion of human IgG1 and
ligand binding portion of TNF-a receptor
Adalimimab (HUMIRA): fully humanized recombinant monoclonal anti-
TNF-a antibody for i.v. use
Therapeutic Uses: Infliximab and Adalimimab: approved for psoriasis, Crohn'sdisease, ankylosing spondylitis, psoriatic arthritis, rheumatoidarthritis, sarcoidosis and ulcerative colitis
Etanercept (various formulations including autoinjector pen):approved for RA; $4.3 billion sales in 2006!! (7th top selling drug)
Side Effects:• Increase incidence of lymphomas and infections [Black box warning]
• Rare cases of demylelination (contra-indicated in MS)
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 24/37
Other Biologics[Recently introduced or in Development]
Efalizumab (RAPTIVA): targets LFA-1 and blocks T celladhesion and activation
Anakinra (KINERET): IL-1 receptor antagonist approvedfor RA
Alefacept (AMEVIVE): Fusion protein that targets CD2,approved for moderate to severe psoriasis
Campath-1H (ALEMTUZUMAB): humanized anti-CD52 Ab depletes T cells, B cells, macrophages and NK cells;
approved for renal transplantation
Anti-IL-12/IL23 antibody: clinical trials for MS and RA
There will be many more new immunosuppressants in
future as we understand the immune system better.
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 25/37
Therapy of Organ Transplantation
For solid organs like heart and kidney it is rarely possible to
achieve perfect HLA matching because of limited supply of organs (exception: live kidney donation from identical twin)
Strong immunosuppression necessary
At most transplant centers intensive biologic induction therapy followed
by maintenance therapyInduction Therapy (delays use of nephrotoxic agents):
• Anti-CD3 Abs ( anti-CD25)• Antithymocyte globin• plasmapheresis if high titers of anti-HLA antibodies
Maintenance Therapy (typically triple therapy at low doses for synergy):• calcineurin inhibitor + glucocorticoid + mycophenolate mofetil• sirolimus + glucocorticoid + mycophenolate mofetil• calcineurin inhibitor + sirolimus + third agent
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 26/37
Therapy of Organ Transplantation
Therapy of Established or Acute Rejection:
• High dose methylprednisolone• Anti-CD3 Abs ( anti-CD25)• Antithymocyte globin
Calcineurin Inhibitors and kidney transplants:• Ultrasound guided biopsy best way to differentiate nephro-toxicity (too much CsA) from rejection (too little CsA)
Future??Currently a lot of research going on into the
possibility of achieving tolerance with sirolimus
(spares Tregs in contrast to CsA) and/or abatacept
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 27/37
Therapy of Autoimmune Diseases
Typically “milder” immunosuppression used than for
prevention of transplant rejection
Choice of therapy should be guided by:
1. Knowledge about specific pathology of
autoimmune disease
2. Careful weighing of benefits of therapy versus sideeffects since treatment is typically for the rest of the patient’s life
Example of a “bad” strategy:In the late 1980s and early 1990s cyclosporine was used to prevent T1DMduring the “honeymoon” period very effective at preventing T1DM butabandoned because of nephrotoxicity
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 28/37
Example: Rheumatoid Arthritis
American College of Rheumatology recommends that
treatment should be chosen based on:
how long a patient has had rheumatoid arthritis the severity of rheumatoid arthritis symptoms
potential for side effects tuberculosis screening (required before starting
biologic DMARDs) cost of treatment (real issue with biologics!!)
patient preference regarding treatment options
DMARD = disease modifying anti-rheumatic drugs (as opposed to NSADs likeaspirin that purely treat the symptoms)
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 29/37
The 2008 ACR Recommendations for Rheumatoid
Arthritis Treatments:
Initiating treatment with methotrexate or leflunomide for most RA patients
Methotrexate plus Plaquenil (hydroxychloroquine) for RA patients with moderateto high disease activity
Treatment with TNF-a antagonist (etanercept, infliximab, adalimumab) plusmethotrexate for patients with early rheumatoid arthritis (symptoms for less than 3
months) and high disease activity
For RA with moderate to long disease duration, TNF-a antagonists for thosewho failed to get a satisfactory response from methotrexate therapy
Abatacept and rituximab should be reserved for patients with at least moderate
disease activity and inadequate treatment response to other agents
Treatment with methotrexate or the biologics should not be resumed or startedduring an active bacterial or viral infection
Severe flair-ups: CsA or methylprednisolone
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 30/37
Example: Multiple Sclerosis
Chronic, immune-mediated demyelinating disease of
the CNS that is characterized by inflammation, gliosisand axonal damage
Most common neurological disease in young adults
(age of onset 15-50 years); affects 400 000 people in the
US and about 2.5 million worldwide
• •
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 31/37
MS is a T cell mediated disease
myelin-antigen specific T cells with a Th1 profile can be
isolated both from the blood and the CSF of MS patients Although myelin-antigen specific T cells are also presentin the blood of healthy controls and occur with the samefrequency, their activation state in MS patients is different.
Myelin-reactive MS patients T cells secrete larger amountsof IL-2, IFN-g and TNF-a than T cells from controls, and arepredominantly of a Th1/Th0 memory phenotype
CD4
CD3Extravasating T cells in apostmortem brain sectionfrom a MS patient
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 32/37
FDA APPROVED TREATMENT
OPTIONS FOR MS
Immunomodulatory drugs:
• IFN-b
• Copaxone (Glatiramer acetate)
• Natalizumab
Immunosuppressive drugs:
• Acute severe attack: methylprednisolone
• Cyclophosphamide and mitoxantrone for secondaryprogressive and primary progressive MS
[Diagnosis and symptoms of MS will be covered in Neurology]
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 33/37
Interferon-b
naturally occurring cytokine with still unknown
mechanism of action:
- suppresses T cell proliferation
- reduces T cell migration into the CNS
- changes cytokine profile from Th1 to Th2 (?)
like most proteins interferons are potentially
immunogenic (especially when produced
recombinantly altered glycosylation) and
neutralizing Abs appear in many patients still hotlydebated whether these antibodies reduce efficacy of
INF-b
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 34/37
Glatiramer Acetate (Copaxone)
random polymer of glutamic acid, lysine, alanine
and tyrosine (which compose MBP) with unclear
mechanism:
1) induction of tolerance to MBP (?)2) induces a population of GA-reactive Th2-type
“regulatory” T cells that secrete Th2 cytokines
in the brain and create an “anti-inflammatory
milieu” either spontaneously or after cross-
stimulation with myelin antigens (?)
long-term treatment also seems to induce serum
Abs
Phase III Trials: Reduction in Annual
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 35/37
Phase III Trials: Reduction in Annual
Relapse Rate
*For patients who had been in the study for 2 years.
Jacobs et al. Ann Neurol. 1996;39:285; IFNB MS Study Group. Neurology . 1993;43:655;
IFNB MS Study Group and University of British Columbia MS/MRI Analysis Group. Neurology . 1995;45:1277; Johnson et al.Neurology . 1995;45:1268; PRISMS Study Group. Lancet. 1998;352:1498;
35
32%
% R
e d u c t i o
n i n r e l a p s e r a t e s
29% 32%31% 29%
Avonex
30 mcg
Betaseron
875-1000 mcg
Copaxone
140 mg
Rebif
66 mcg
Rebif
132 mcg
P=0.002* P=0.0004
P<0.0001
P<0.0001P=0.007
30
25
20
15
10
5
0
18%
P=0.04
INF-b INF-b
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 36/37
Natalizumab (Tysabri)
Anti-VLA-4 Monoclonal Antibody
66% reduction in relapses
92% reduction in active MRI lesions
Monthly IV administration
2/1200 patients treated developed PML and died
Tysabri removed from the market in early 2005
March 2006: an FDA advisory committeerecommended that it should return to the market(massive pressure from MS patients and NMSS)
7/29/2019 Immunosuppressants 8182
http://slidepdf.com/reader/full/immunosuppressants-8182 37/37
Symptom Management of MS
PrimaryCaused by actual demyelination within the CNS
Fatigue, tremor, incontinence, spasticity, depression
antidepressants, anti-spastics
SecondaryCaused by failure to manage the primary
Contractures, decubiti, fractures, muscle atrophy
physiotherapy
TertiaryPsychological, social, marital, vocational, personal antidepressants, Viagra, Life-style changes